Special Issue "Hormones and Carcinogenesis"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 July 2014)

Special Issue Editor

Guest Editor
Prof. Dr. Robin Fuchs-Young

Department of Molecular and Cellular Medicine, College of Medicine and the Institute for Bioscience and Technology, 208 Reynolds Medical Building, Texas A&M Health Science Center College Station, TX 77843-1114, USA
E-Mail

Special Issue Information

Dear Colleagues,

Hormones play a critical role in cancer development in a variety of organs, including breast, uterus, ovary, prostate, testes, liver and others. Recent investigations have revealed that “cross-talk” between hormone and growth factor signaling networks affect the acquisition of the malignant phenotype, often in a tissue specific fashion. Environmental factors acting as hormonal mimics (endocrine disruptors) can alter both genetic integrity and epigenetic programs, and these effects can be further modulated by exposures during specific developmental periods (“windows of susceptibility”). This special issue of Hormones and Carcinogenesis is intended to incorporate a range of topics related to the contributions of steroid and peptide hormones to susceptibility, incidence, progression and treatment of cancer. We invite authors to submit primary papers as well as thoughtful reviews that elucidate mechanisms and pathways of hormonal carcinogenesis and/or that introduce new hypotheses and paradigms.

Prof. Dr Robin Fuchs-Young
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

Keywords

  • hormone
  • peptide
  • steroid
  • receptor
  • carcinogenesis
  • signaling/signal transduction
  • cross talk
  • endocrine disruptors

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Review

Open AccessReview Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
Cancers 2012, 4(4), 969-988; doi:10.3390/cancers4040969
Received: 4 July 2012 / Revised: 9 August 2012 / Accepted: 10 September 2012 / Published: 25 September 2012
Cited by 7 | PDF Full-text (190 KB) | HTML Full-text | XML Full-text
Abstract
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers
[...] Read more.
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy. Full article
(This article belongs to the Special Issue Hormones and Carcinogenesis)
Open AccessReview Endometrial Serous Carcinoma: Its Molecular Characteristics and Histology-Specific Treatment Strategies
Cancers 2012, 4(3), 799-807; doi:10.3390/cancers4030799
Received: 4 June 2012 / Revised: 28 July 2012 / Accepted: 1 August 2012 / Published: 7 August 2012
Cited by 3 | PDF Full-text (933 KB) | HTML Full-text | XML Full-text
Abstract
Endometrial cancer is the fourth most common malignancy in women, with most cases being classified as early stage endometrioid tumors that carry a favorable prognosis. The endometrial serous histological subtype (ESC), however, while only accounting for 10% of all endometrial cancers is responsible
[...] Read more.
Endometrial cancer is the fourth most common malignancy in women, with most cases being classified as early stage endometrioid tumors that carry a favorable prognosis. The endometrial serous histological subtype (ESC), however, while only accounting for 10% of all endometrial cancers is responsible for a disproportionate number of deaths. Unlike the estrogen-dependent, well differentiated endometrioid tumors, which are commonly associated with a younger age of onset, ESCs are estrogen-independent and tend to present at an advanced stage and in older women. Treatment for ESC entails aggressive surgery and multimodal adjuvant therapy. In this review, we describe the clinical behavior, molecular aspects, and treatment strategies for ESC. Full article
(This article belongs to the Special Issue Hormones and Carcinogenesis)

Journal Contact

MDPI AG
Cancers Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
cancers@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Cancers
Back to Top